Mobile

Study of the efficacy of prolonged release oxycodone/naloxone (OXN PR), compared to prolonged release oxycodone (Oxy PR), for the reduction of the intensity of opioid-induced constipation symptoms in ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-012051-20

Study of the efficacy of prolonged release oxycodone/naloxone (OXN PR), compared to prolonged release oxycodone (Oxy PR), for the reduction of the intensity of opioid-induced constipation symptoms in patients treated for cancer or non-cancer pain: A randomised, double-blind, controlled, multicentre study

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this trial is to study the efficacy of oxycodone/naloxone prolonged release tablets (OXN PR), compared to oxycodone prolonged release tablets (Oxy PR), for the reduction of the intensity of opioid-induced constipation symptoms in patients treated for cancer or non-cancer pain.

Critère d'inclusion

  • For both compounds, treatment for cancer or non-cancer pain, adult subjects with a diagnosis of cancer pain or non-cancer pain such as chronic low back pain, osteoarthritis or other. Only for targinact, the intention of naloxone is to reduce the intensity of opioid-induced constipation symptoms

Liens